At present, Xinyi has become one of the industrial entities with the most complete product varieties and dosage forms in China. It has 11 major industrial enterprises, 2 major commercial companies, 1 procurement center, 1 municipal research and development center, and 2 joint ventures. It has nearly 1000 product approvals, covering 14 treatment fields, covering 20 dosage forms, and 2 national first-class new drug varieties. There are 405 product specifications in sales (of which 149 varieties and 270 product specifications have entered the latest national basic drug catalog, accounting for nearly half of the chemical basic drug catalog). On the basis of maintaining its competitive advantage in chemical preparations, Xinyi has also established a leading position in microecological preparations nationwide, as well as four characteristic dosage forms: aerosols, eye drops, soft capsules, and sustained-release preparations.

At present, Xinyi has become one of the industrial entities with the most complete product varieties and dosage forms in China. It has 11 major industrial enterprises, 2 major commercial companies, 1 procurement center, 1 municipal research and development center, and 2 joint ventures. It has nearly 1000 product approvals, covering 14 treatment fields, covering 20 dosage forms, and 2 national first-class new drug varieties. There are 405 product specifications in sales (of which 149 varieties and 270 product specifications have entered the latest national basic drug catalog, accounting for nearly half of the chemical basic drug catalog). On the basis of maintaining its competitive advantage in chemical preparations, Xinyi has also established a leading position in microecological preparations nationwide, as well as four characteristic dosage forms: aerosols, eye drops, soft capsules, and sustained-release preparations.

Hongqiao Pharmaceutical is a brand under Shanghai Hongqiao Pharmaceutical Co., Ltd. Shanghai Hongqiao Pharmaceutical Co., Ltd. was founded on March 30, 1982, with its main address at 7600 Zhongchun Road, Minhang District, Shanghai; Our main business includes retail of drugs, sales of medical devices (see license for details), thermometers, sphygmomanometers, magnetic therapy equipment, medical defatting gauze, medical hygiene masks, household blood glucose meters, blood glucose test strips, pregnancy diagnosis test strips (early pregnancy test strips), condoms, contraceptive caps, wheelchairs, medical sterile gauze, hardware and electrical appliances, cultural goods, general merchandise, cosmetics, food distribution, rental of self owned houses, business consulting (excluding brokers), warehousing management (excluding dangerous goods), and import and export of goods and technology. Wait. The nature of the company is limited liability company (invested or controlled by natural persons), with a registered capital of RMB 124.166296 million.

Shanghai Suhao Yiming Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of Anke Biotechnology), established in 2001, is a high-tech enterprise mainly engaged in research, development, production, and sales of various GMP peptide raw materials and drugs. Experimental and production facilities with international advanced level: fully automatic peptide synthesis system, separation and purification system, freeze-drying system and other instruments and equipment. On the basis of introducing, digesting, and absorbing international advanced peptide synthesis production technology, we have established a leading high-tech platform for the large-scale research and development of active small molecule peptide drugs and precursors in China. We have independently developed a unique solid-phase synthesis process route suitable for industrial production, providing peptide preparation enterprises at home and abroad with highly cost-effective and high-quality peptide raw materials. At present, there are more than 40 peptide active pharmaceutical ingredients that have been listed or are in the clinical stage both domestically and internationally. The breadth and production of the products are leading in China. The company provides high-quality peptide products, peptide purification services, peptide synthesis reagents, and technical consulting services to users.

At present, Xinyi has become one of the industrial entities with the most complete product varieties and dosage forms in China. It has 11 major industrial enterprises, 2 major commercial companies, 1 procurement center, 1 municipal research and development center, and 2 joint ventures. It has nearly 1000 product approvals, covering 14 treatment fields, covering 20 dosage forms, and 2 national first-class new drug varieties. There are 405 product specifications in sales (of which 149 varieties and 270 product specifications have entered the latest national basic drug catalog, accounting for nearly half of the chemical basic drug catalog). On the basis of maintaining its competitive advantage in chemical preparations, Xinyi has also established a leading position in microecological preparations nationwide, as well as four characteristic dosage forms: aerosols, eye drops, soft capsules, and sustained-release preparations.

At present, the main product production capacity is 1.1 million tons of urea, 700000 tons of methanol, 300000 tons of ethylene glycol, 300000 tons of hydrogen peroxide, 260000 tons of styrene, 200000 tons of polystyrene, 100000 tons of biodegradable plastics (PBAT), 30000 tons of isopropylamine, 20000 tons of morpholine, 6000 tons of diethylene glycol amine, and 6000 tons of nitromethylmorpholine. Among them, urea and methanol products are well-known brand products in Anhui Province, with production scale ranking first in Anhui Province; Morpholine products are well-known brand products and high-tech products in Anhui Province, with 6 invention patents and the production capacity ranking first in Asia; Diethylene glycol amine products are high-tech products in Anhui Province, with 4 invention patents. They are independently developed and have independent intellectual property rights by our company, filling the domestic gap. The trademark "Haoyuan and Tu" has been recognized as a well-known trademark by the Trademark Office of the State Administration for Industry and Commerce.